Abstract
Group B Streptococcus (GBS) disease in neonates occurs in two forms: early-onset disease (EOD), (day 0-6), and late-onset disease (LOD), (day 7-90). This review investigates that risk-based intrapartum screening and antibiotics have reduced the incidence of EOD, but not LOD, in Denmark. No clinical or laboratory tests can rule out GBS disease at symptom onset. Thus, a high proportion of uninfected infants receive antibiotics, although this varies widely, and may be reduced by strategies of antibiotic stewardship. A future GBS vaccine for pregnant women may potentially reduce disease burden and antibiotic exposure.
| Bidragets oversatte titel | Not Available |
|---|---|
| Originalsprog | Dansk |
| Artikelnummer | V01240022 |
| Tidsskrift | Ugeskrift for laeger |
| Vol/bind | 186 |
| DOI | |
| Status | Udgivet - 24 jun. 2024 |
Emneord
- Humans
- Streptococcal Infections/diagnosis
- Infant, Newborn
- Streptococcus agalactiae/isolation & purification
- Anti-Bacterial Agents/therapeutic use
- Female
- Pregnancy
- Denmark/epidemiology
- Pregnancy Complications, Infectious/diagnosis
- Infant
- Streptococcal Vaccines/administration & dosage
- Infectious Disease Transmission, Vertical/prevention & control
Fingeraftryk
Udforsk hvilke forskningsemner 'Group B streptococci in newborns in the first three months of life' indeholder.Citationsformater
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver